Dr. Feld graduated from medical school at the University of Toronto in 1997 and then completed residency programs in Internal Medicine and Gastroenterology. Following his clinical training, Dr. Feld focused on developing skills in clinical and laboratory research in liver disease, with a particular interest in viral hepatitis. He completed a clinical research fellowship in hepatology and then spent 4 years doing clinical and laboratory research in the Liver Diseases Branch of the National Institutes of Health. He received a Masters of Public Health with a focus on Infectious Diseases as a Sommer Scholar from Johns Hopkins University and has worked extensively abroad, maintaining a strong interest in International Health. Curently, Dr. Feld is clinician-scientist based at the Toronto Western Hospital Liver Clinic and the McLaughlin-Rotman Centre for Global Health.
Dr. Felds research focuses on understanding treatment non-response in hepatitis C and more broadly on understanding the antiviral immune response and developing new strategies for the treatment of viral hepatitis.
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Gut. 2019 Aug 28;:
Gastroenterol Hepatol (N Y). 2019 Jun;15(6):303-306
Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma.
Gastroenterology. 2019 Jul 30;:
Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores.
Gastroenterology. 2019 Jul 26;:
Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B.
Hepatology. 2019 Jul 15;:
Patterns of drug, alcohol use and injection equipment sharing among people with recent injecting drug use or receiving opioid agonist treatment during and following hepatitis C virus treatment with direct-acting antiviral therapies: An international...
Clin Infect Dis. 2019 Jul 11;:
J Manag Care Spec Pharm. 2019 Jun;25(6):697-704
Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults with Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6.
J Viral Hepat. 2019 May 20;:
Ann Hepatol. 2019 Apr 25;:
Clin Liver Dis (Hoboken). 2018 Nov;12(5):125-129
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Scientist, Sandra Rotman Centre for Global Health, Toronto, Ontario, Canada
Research Director, Gastroenterology, Medicine/University of Toronto, Francis Family Liver Clinic - Toronto Western Hospital, Toronto, Ontario, Canada
Associate Professor of Medicine, University of Toronto, Toronto, Ontario, Canada